Delivery Order SPE2DB20D2001-SPE2DB25FPMNH
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials, with a ceiling value of $18,294.14. This competitively awarded, firm fixed-price delivery order is set to be completed by July 31, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 11, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) vials valued at $6,821.38. This non-competitive, firm fixed-price delivery order is due for completion by December 12, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA, supporting federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials, with a ceiling value of $9,384.50. This non-set-aside, competitively awarded delivery order utilizes firm fixed price pricing and is scheduled for completion by November 5, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order operates under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 20, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with a contract ceiling value of $1,820.04. This non-set-aside, competitively awarded delivery order features firm fixed pricing and is scheduled for ultimate completion on November 21, 2025. The performance location is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 26, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) in 3 ml vials, with a ceiling value of $10,727.51 and an ultimate completion date of November 28, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded under competitive procedures. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $42,011.63. This firm fixed-price delivery order, which is set to be completed by August 5, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement within the Defense Logistics Agency's medical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with a ceiling value of $31,785.02. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials, with a contract ceiling value of $49,655.94. This is a firm fixed-price delivery order issued under a competitive procurement with no set-aside designation. The award reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal medical supply chains, with performance to take place at the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials, with a contract ceiling value of $5,010.26. This is a firm fixed price delivery order with an ultimate completion date of August 26, 2025, and represents a non-set-aside competitive award. The pharmaceutical product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $37,730.25. This competitively awarded, firm fixed-price delivery order is set to be completed by August 20, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical supply...
- SPE2DB20D2001Indefinite Delivery Contract
- SPE2DB20D2001-SPE2DB25FPMNHDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials, with a contract ceiling value of $18,321.85. This non-set-aside, competitively awarded delivery order reflects firm fixed pricing and is scheduled for completion by April 25, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement needs, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle provides comprehensive global pharmaceutical support, enabling the contractor to supply an extensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The company's contract portfolio demonstrates significant experience fulfilling federal medical supply requirements across multiple therapeutic domains, including diabetes medications, neurological treatments, pain management pharmaceuticals, and specialized medical supplies to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.3k | 4/24/25 |